Sarepta Shares Community Letter Regarding ELEVIDYS Label Update

November 18, 2025

On November 16, 2025, Sarepta Therapeutics Inc. shared a Community Letter with updates regarding the label for ELEVIDYS, Sarepta’s approved gene therapy for Duchenne muscular dystrophy.

To view Sarepta’s Community Letter, please click here